Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 study of RP L102 in the patients with Fanconi's-anaemia

Trial Profile

Phase 1/2 study of RP L102 in the patients with Fanconi's-anaemia

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mozafancogene autotemcel (Primary)
  • Indications Fanconi's anaemia
  • Focus Therapeutic Use
  • Acronyms FANCOLEN-I
  • Most Recent Events

    • 06 Nov 2023 According to a Rocket Pharmaceuticals media release, Product filings for RP-L102 anticipated in the first half of 2024 in the U.S. and Europe. The company is finalizing the CMC package with the FDA.
    • 09 Jan 2023 According to a Rocket Pharmaceuticals media release, BLA filling for FA is on track for Q4 2023.
    • 13 May 2021 According to a Rocket Pharmaceuticals media release, results from this study were presented at the upcoming 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top